SEC Form 4 · accession 0001628280-26-060572
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Eric Davis
Officer — EVP, Chief Legal Officer
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 6:41 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 2, 2026 | S | 17,557 | $66.284 | D | 61,003 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.